Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K033610
    Date Cleared
    2003-12-05

    (18 days)

    Product Code
    Regulation Number
    862.1475
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    HDL-CHOLESTEROL PLUS 2ND GENERATION

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    HDL-C plus 2nd generation is an enzymatic in-vitro assay for the direct quantitative determination of high-density lipoprotein cholesterol (HDL-C) in human serum and plasma on automated clinical chemistry analyzers.

    Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.

    Device Description

    The HDL-Cholesterol plus 2nd Generation test principle uses magnesium sulfate and dextran sulfate to form water-soluble complexes with LDL, VLDL, and chylomicrons which are resistant to PEG-modified enzymes. The cholesterol concentration of HDL-cholesterol is determined enzymatically by cholesterol esterase and cholesterol oxidase coupled with PEG. The color intensity of the blue quinoneimine dye formed is directly proportional to the HDL-cholesterol concentration and is measured photometrically.

    AI/ML Overview

    This is a 510(k) summary for a medical device, which generally does not include the detailed study design elements you've requested (such as sample size, ground truth establishment methods, or expert qualifications for test/training sets). The primary purpose of a 510(k) summary is to demonstrate "substantial equivalence" to a predicate device, focusing on performance characteristics and how they compare.

    However, I can extract the information that is present and provide a table for acceptance criteria and device performance based on the available text.

    Here's a breakdown of the available information:

    1. Table of Acceptance Criteria and Reported Device Performance

    The 510(k) summary does not explicitly state "acceptance criteria" in a quantitative manner for specific performance metrics like accuracy, sensitivity, or specificity. Instead, it describes key performance characteristics and compares them to the predicate device, implying that meeting or being comparable to the predicate's performance is the implicit acceptance criterion for substantial equivalence.

    Performance CharacteristicPredicate Device (HDL-C plus - K000568) (Implicit Acceptance Criteria)Modified Device (HDL-Cholesterol plus 2nd generation) (Reported Device Performance)
    Intended UseFor the direct quantitative determination of high-density lipoprotein cholesterol (HDL-cholesterol) in serum and plasma.HDL-C plus 2nd generation is an enzymatic in-vitro assay for the direct quantitative determination of high-density lipoprotein cholesterol (HDL-C) in human serum and plasma on automated clinical chemistry analyzers.
    MethodHomogeneous enzymatic colorimetricSame
    Sample typeSerum, Li-, Na-Heparin plasma, EDTA plasmaSerum, Li-, Na-, NH4- Heparin plasma, EDTA plasma
    Measuring range3 - 120 mg/dlSame
    Formulation R1Sulfated alpha-cyclodextrin, dextran sulfate, magnesium chloride, HSDA, ascorbate oxidase (Acremonium), peroxidase (horseradish), MOPS buffer, preservativeDextran sulfate, magnesium sulfate heptahydrate, HSDA, ascorbate oxidase (Eupenicillium sp., recombinant), peroxidase (horseradish), MOPS buffer, preservative
    Formulation R2PEG cholesterol esterase (Pseudomonas), PEG cholesterol oxidase (Pseudomonas), peroxidase (horseradish), 4-aminophenazone, PIPES buffer, preservativePEG cholesterol esterase (Pseudomonas), PEG cholesterol oxidase (Streptomyces sp., recombinant) peroxidase (horseradish), 4-amino-antipyrine, PIPES buffer, preservative

    Notes on Acceptance Criteria: The primary acceptance criterion for a 510(k) is "substantial equivalence" to a predicate device. This means the new device must be as safe and effective as the predicate. In this context, "performance" refers to demonstrating that the modified device functions comparably in its intended use, measuring range, method, and sample types, despite minor formulation changes. The NCEP guidelines for expected values are provided as context for interpretation, not as a direct performance metric for the device itself.

    2. Sample size used for the test set and the data provenance:

    • The 510(k) summary does not provide details on sample sizes for any test sets.
    • Data provenance is not explicitly mentioned, but given it's a product from Roche Diagnostics Corporation (Indianapolis, IN, USA), it's highly probable that the studies were conducted in the US. The summary does not specify if data was retrospective or prospective.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

    • This information is not provided in the 510(k) summary. For an in-vitro diagnostic (IVD) like an HDL-Cholesterol assay, ground truth is typically established by reference methods or validated laboratory measurements, not by expert interpretation in the same way as, for example, a medical imaging device. However, the document does not detail how "ground truth" (i.e., true HDL-C values for comparison) was established for any validation studies.

    4. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

    • This information is not applicable or provided. Adjudication methods are typically used in studies involving subjective interpretation (e.g., image reading by multiple experts). For a quantitative IVD, the "adjudication" would be based on the objective comparison of the device's results to a reference method.

    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

    • This information is not applicable or provided. MRMC studies are specific to devices that assist human readers (e.g., AI-powered diagnostic software). This device is a direct quantitative assay, not an assistive reading device.

    6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

    • This device, an enzymatic in-vitro assay, inherently functions as a "standalone" measurement system. It directly produces a quantitative result (HDL-C concentration) without requiring human interpretation beyond standard laboratory procedures and clinical context. The entire device's performance would be considered standalone.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

    • The 510(k) summary does not explicitly state the type of ground truth used for performance comparison. For quantitative IVDs, ground truth is usually established using:
      • Reference methods: Highly accurate and precise laboratory methods, often more complex or expensive than routine assays.
      • Calibrators and controls: Materials with known and certified concentrations of the analyte.
      • Patient samples compared against the predicate device or a clinical gold standard.

    8. The sample size for the training set:

    • This information is not provided and is generally not applicable in the context of an enzymatic chemical assay. These assays rely on validated chemical reactions, not machine learning algorithms that require "training sets" in the conventional sense.

    9. How the ground truth for the training set was established:

    • This information is not provided and not applicable as there is no "training set" in the context of this type of enzymatic assay.
    Ask a Question

    Ask a specific question about this device

    K Number
    K012286
    Date Cleared
    2001-08-08

    (19 days)

    Product Code
    Regulation Number
    862.1475
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    MODIFICATION TO:COBAS INTEGRA HDL-CHOLESTEROL PLUS 2ND GENERATION

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The cassette COBAS Integra HDL-Cholesterol plus 2nd Generation contains an in vitro diagnostic reagent system intended for use on COBAS Integra systems for the quantitative determination of HDL-cholesterol concentration in serum and plasma. A lipoprotein test system is a device intended to measure lipoprotein in serum and plasma. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.

    Device Description

    The HDL-Cholesterol plus 2nd Generation test principle uses magnesium sulfate and dextran sulfate to form water-soluble complexes with LDL, VLDL, and chylomicrons which are resistant to PEG-modified enzymes. The cholesterol concentration of HDL-cholesterol is determined enzymatically by cholesterol esterase and cholesterol oxidase coupled with PEG. The color intensity of the blue quinoneimine dye formed is directly proportional to the HDL-cholesterol concentration. It is determined by measuring the increase in absorbance at 583 nm.

    AI/ML Overview

    The provided text does not contain detailed acceptance criteria, the study or performance data of the HDL-Cholesterol plus 2nd Generation device.

    The document is a 510(k) summary and an FDA clearance letter, which primarily focuses on establishing substantial equivalence to a predicate device (Roche/Hitachi HDL-Cholesterol plus 2nd generation assay, K963213). It describes the device, its intended use, and indicates that it has the "same intended use and indication for use, the same scientific principle, the same formulation and similar application parameters" as the predicate device.

    Therefore, I cannot provide the requested information, specifically:

    1. A table of acceptance criteria and the reported device performance.
    2. Sample size used for the test set and data provenance.
    3. Number of experts and their qualifications for ground truth.
    4. Adjudication method for the test set.
    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done.
    6. If a standalone performance study was done.
    7. The type of ground truth used.
    8. The sample size for the training set.
    9. How the ground truth for the training set was established.

    This type of detailed performance data is typically found in the full 510(k) submission, specifically in the performance testing sections, which are not included in this summary document.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1